October 15, 2016
2 min read
Save

Treat-and-extend dosing reduces treatment burden in TREX-AMD trial

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

CHICAGO — Treatment burden was significantly reduced with treat-and-extend dosing vs. monthly dosing of ranibizumab through 2 years in the TREX-AMD study, an investigator reported here.

Charles C. Wykoff , MD, PhD, presented the study results at Retina Subspecialty Day preceding the American Academy of Ophthalmology meeting. The trial was funded by a grant from Genentech.

Charles C. Wykoff

Charles C. Wykoff

The objective of a treat-and-extend approach to wet AMD management is to individualize dosing in order to minimize treatment burden while optimizing vision benefit, Wykoff said.

In the multicenter prospective TREX-AMD trial, 60 treatment-naive eyes with wet age-related macular degeneration were randomized 1:2, with 20 eyes receiving monthly ranibizumab treatment and 40 receiving treat-and-extend ranibizumab. TREX eyes were given monthly dosing for at least 3 months until achieving a dry macula, then injection intervals were incrementally increased to a maximum of 12 weeks.

Sixty-eight percent of the TREX arm achieved a dry macula and intervals were extended following three or four injections; 8% of TREX eyes never achieved a dry macula.

Regarding treatment burden through 2 years, a statistically significant difference between the two groups was seen, with the TREX group receiving a mean of 18.6 injections and the monthly group receiving a mean of 25.5 injections (P <.0001).

Regarding mean change in visual acuity, “Both the monthly and the TREX arms performed well, gaining a mean 10.5 and 8.7 letters, respectively, with no significant differences between the groups,” Wykoff said. However, whereas 20% of the monthly arm and 28% of the TREX arm gained at least 15 letters and no eyes in the monthly arm lost 15 letters of visual acuity, 10% of eyes in the TREX group did lose 15 letters or more. Wykoff associated the vision loss with progressive macular atrophy as a contributing factor.

“Importantly, no patient lost vision due to exudative disease recurrence while the interval between treatments was extended,” Wykoff said. by Patricia Nale, ELS

 

Reference:

Wykoff C. Monthly vs treat and extend for neovascular AMD: TREX-AMD 24-month outcomes. Presented at: American Academy of Ophthalmology annual meeting; Oct. 14-18, 2016; Chicago.

 

Disclosure: Wykoff reports he is a consultant for Allergan, Alimera, Bayer, Clearside, DORC, Genentech, ONL Therapeutics and Regeneron, is a speaker for Allergan and Regeneron, and receives research support from Acucela, Alcon/Novartis, Alimera, Allergan, Apellis, Clearside, DORC, DRCR.net, Genentech/Roche, Iconic, Ophthotech, Santen, Regeneron/Bayer, Thrombogenics and Tyrogenex. The study was funded by a grant from Genentech.